Biotech Values

[DewDiligence]

DES notes from ABT’s 3Q10 CC:

• ABT’s 3Q10 DES revenues (including Promus royalties) were $450M, +37% YoY with very string growth in Japan and China. DES’s now comprise 5% of ABT’s overall corporate revenue.

• US market share of Xience+Promus: 60%.

• Industry-wide DES penetration in US PCI procedures: 79%.